Developer docs
API playgroundTry for free, no card

Search company profiles

Seamless Therapeutics

Full company profile

uuid0000r7v

Namestring
Seamless Therapeutics
Legal namestring
Seamless Therapeutics GmbH
Websiteurl
seamlesstx.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Seamless Therapeutics is a preclinical-stage German biotechnology company developing a proprietary gene editing platform based on programmable recombinases. Founded in 2023 and headquartered in Dresden, Germany with a US office in Lexington, Massachusetts, the company is building an alternative to CRISPR/Cas gene editing that enables precise, large DNA fragment insertions or deletions anywhere in the genome without introducing additional mutations. The core technology was developed by Prof. Frank Buchholz at TU Dresden and refined by co-founder Felix Lansing during his PhD research, resulting in 7 foundational patents and licensed IP rights that anchor the platform.

The company's product strategy centers on a single platform technology — site-specific recombinases that can be programmed for specific therapeutic targets — which it is applying to develop a pipeline of disease-modifying candidates across a broad spectrum of genetic disease indications, with hearing loss as the lead area via a major partnership. Seamless does not sell products directly; instead, it generates revenue through licensing and research collaboration agreements with pharmaceutical partners, receiving upfront payments, committed R&D funding, development and commercial milestones, and tiered royalties on approved products. Its primary customer relationship is a January 2026 global research collaboration and licensing agreement with Eli Lilly valued at up to $1.12 billion for hearing loss treatments.

The company is venture-backed, having closed a $12.5 million seed round in March 2023 co-led by Wellington Partners and Forbion, with additional non-dilutive support from the German government's BMBF GO-Bio program and UCB Ventures as a listed investor. Leadership includes President and CEO Albert Seymour (formerly of Homology Medicines, Shire, and Pfizer) and Chief Development Officer Deborah Kinch (formerly of Homology Medicines and Biogen), reflecting a deliberate build-out of US-based drug development expertise to support the platform's transition toward first-in-human clinical trials.

Short descriptiontext

Seamless Therapeutics is a preclinical German biotech developing programmable recombinase gene editing technology as an alternative to CRISPR/Cas, licensing its platform to pharmaceutical partners for large-fragment DNA corrections in genetic diseases, with Eli Lilly as its lead partner for hearing loss treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDresden, Germany
HQ citystring
Dresden
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene editing platform, recombinase technology, precision genome editing, genetic disease therapy, biotech licensing
Industry3 codes
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Editing Biotechnology Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research Collaboration Agreements
TypeLicensing Royalties
Description

Seamless enters into strategic research collaborations with pharmaceutical companies where they design and program site-specific recombinases for specific therapeutic applications. The company receives upfront payments, committed R&D funding, and potential milestone payments.

hubs.li
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

License agreements that provide exclusive rights to pharmaceutical partners for preclinical, clinical development, and commercialization. Seamless receives upfront payments, R&D funding, development and commercial milestones, and tiered royalties on approved products.

genengnews.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Seamless Therapeutics develops a proprietary programmable recombinase-based gene editing platform that enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. The platform is being applied to build a pipeline of disease-modifying gene therapy candidates, with the lead focus on hearing loss in collaboration with Eli Lilly, and is monetized through licensing and research collaboration agreements with pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Potential $1.12 billion deal value from Eli Lilly partnership including upfront, R&D funding, and milestone payments
+1 more record
Product overview1 text field

Seamless Therapeutics operates as a single-platform biotechnology company developing a proprietary programmable recombinase gene editing technology. Their core platform enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations, representing an alternative approach to CRISPR/Cas gene editing. The company is applying this technology to develop a pipeline of disease-modifying product candidates across a broad spectrum of genetic disease indications. As of 2026, the company has entered a collaboration with Eli Lilly to develop treatments for hearing loss using this platform technology.

Product and service1 record
1Programmable Recombinase Gene Editing Platform
CategoryGene Editing Biotechnology Platform
Description

A proprietary gene editing technology platform based on programmable recombinases that enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. The platform uses site-specific recombinases to correct gene mutations and is being developed for treating genetic diseases, including hearing loss via the Eli Lilly collaboration.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-28
Description

Eli Lilly entered into a global research collaboration and licensing agreement with Seamless Therapeutics to develop programmable recombinase-based gene-editing treatments for hearing loss. Seamless designs and programs site-specific recombinases to correct gene mutations, while Lilly gains exclusive license to advance candidates through preclinical and clinical development and commercialization. Deal could exceed $1.12 billion in total payouts for Seamless across upfront payments, R&D funding, and milestone terms.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing precision genetic medicines using base editing technology. Directly comparable to Seamless as a next-generation gene editing platform pursuing therapeutic applications, with differentiated editing chemistry targeting similar disease indications.

TypeDirect peer
Description

Clinical-stage gene editing company developing CRISPR-based medicines for serious diseases. Comparable to Seamless as a genome editing platform pursuing in vivo and ex vivo therapeutic applications, with overlapping target indications in genetic diseases.

TypeDirect peer
Description

Clinical-stage biotechnology company developing in vivo base editing treatments for cardiovascular disease. Comparable to Seamless as a gene editing platform pursuing in vivo therapeutic applications, with focus on durable treatments for genetic diseases.

TypeDirect peer
Description

Clinical-stage biotechnology company developing ARCUS gene editing platform for in vivo and ex vivo therapeutic applications. Directly comparable to Seamless as a novel gene editing platform pursuing therapeutic applications with differentiated editing architecture.

TypeDirect peer
Description

Clinical-stage biotechnology company developing prime editing technology for precise gene corrections. Directly comparable to Seamless as a next-generation gene editing platform seeking to expand the scope of addressable genetic edits beyond traditional CRISPR/Cas approaches.

TypeEmerging player
Description

Preclinical-stage biotechnology company developing Gene Writing technology for precise genomic alterations. Comparable to Seamless as an emerging next-generation gene editing platform pursuing large DNA modifications for therapeutic applications.

TypeBroad incumbent
Description

Clinical-stage biotechnology company developing zinc finger nuclease-based genome editing and gene therapy. Comparable to Seamless as a pioneering gene editing platform pursuing therapeutic applications across multiple genetic disease indications with a non-CRISPR editing approach.

TypeEmerging player
Description

Preclinical-stage biotechnology company developing in vivo gene editing and delivery technology for genomic medicines. Comparable to Seamless as an emerging gene editing platform, and notably a current board affiliation of Seamless CEO Albert Seymour, suggesting direct professional overlap in the field.

TypeDirect peer
Description

Clinical-stage biotechnology company developing in vivo CRISPR/Cas9-based gene editing therapies. Directly comparable to Seamless as a genome editing platform company pursuing therapeutic applications across multiple genetic diseases, with overlapping modalities despite using a different editing architecture.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on CRISPR/Cas9 gene-editing therapies for hemoglobinopathies, oncology, and regenerative medicine. Directly comparable to Seamless as a genome editing platform company pursuing multiple therapeutic indications through a core editing technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seamless Therapeutics

Gene Editing Biotechnology Platformseamlesstx.com

Seamless Therapeutics is a preclinical German biotech developing programmable recombinase gene editing technology as an alternative to CRISPR/Cas, licensing its platform to pharmaceutical partners for large-fragment DNA corrections in genetic diseases, with Eli Lilly as its lead partner for hearing loss treatments.

What Seamless Therapeutics does

Seamless Therapeutics is a preclinical-stage German biotechnology company developing a proprietary gene editing platform based on programmable recombinases. Founded in 2023 and headquartered in Dresden, Germany with a US office in Lexington, Massachusetts, the company is building an alternative to CRISPR/Cas gene editing that enables precise, large DNA fragment insertions or deletions anywhere in the genome without introducing additional mutations. The core technology was developed by Prof. Frank Buchholz at TU Dresden and refined by co-founder Felix Lansing during his PhD research, resulting in 7 foundational patents and licensed IP rights that anchor the platform.

The company's product strategy centers on a single platform technology — site-specific recombinases that can be programmed for specific therapeutic targets — which it is applying to develop a pipeline of disease-modifying candidates across a broad spectrum of genetic disease indications, with hearing loss as the lead area via a major partnership. Seamless does not sell products directly; instead, it generates revenue through licensing and research collaboration agreements with pharmaceutical partners, receiving upfront payments, committed R&D funding, development and commercial milestones, and tiered royalties on approved products. Its primary customer relationship is a January 2026 global research collaboration and licensing agreement with Eli Lilly valued at up to $1.12 billion for hearing loss treatments.

The company is venture-backed, having closed a $12.5 million seed round in March 2023 co-led by Wellington Partners and Forbion, with additional non-dilutive support from the German government's BMBF GO-Bio program and UCB Ventures as a listed investor. Leadership includes President and CEO Albert Seymour (formerly of Homology Medicines, Shire, and Pfizer) and Chief Development Officer Deborah Kinch (formerly of Homology Medicines and Biogen), reflecting a deliberate build-out of US-based drug development expertise to support the platform's transition toward first-in-human clinical trials.

Seamless Therapeutics firmographics

Firmographics
Name
Seamless Therapeutics
Legal name
Seamless Therapeutics GmbH
Website
https://seamlesstx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Seamless Therapeutics is a preclinical German biotech developing programmable recombinase gene editing technology as an alternative to CRISPR/Cas, licensing its platform to pharmaceutical partners for large-fragment DNA corrections in genetic diseases, with Eli Lilly as its lead partner for hearing loss treatments.
Ownership category
akta.pro rank

Seamless Therapeutics industry classification

Industry
Product category
Gene Editing Biotechnology Platform
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Gene editing platform
  • Recombinase technology
  • Precision genome editing
  • Genetic disease therapy
  • Biotech licensing

Where Seamless Therapeutics is headquartered

Location

Headquarters

HQ city
Dresden
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Seamless Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Research Collaboration Agreements: Seamless enters into strategic research collaborations with pharmaceutical companies where they design and program site-specific recombinases for specific therapeutic applications. The company receives upfront payments, committed R&D funding, and potential milestone payments.
  2. Licensing and Milestone Payments: License agreements that provide exclusive rights to pharmaceutical partners for preclinical, clinical development, and commercialization. Seamless receives upfront payments, R&D funding, development and commercial milestones, and tiered royalties on approved products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Seamless Therapeutics product offering

Product offering

Core offering

Seamless Therapeutics develops a proprietary programmable recombinase-based gene editing platform that enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. The platform is being applied to build a pipeline of disease-modifying gene therapy candidates, with the lead focus on hearing loss in collaboration with Eli Lilly, and is monetized through licensing and research collaboration agreements with pharmaceutical partners.

Product overview

Seamless Therapeutics operates as a single-platform biotechnology company developing a proprietary programmable recombinase gene editing technology. Their core platform enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations, representing an alternative approach to CRISPR/Cas gene editing. The company is applying this technology to develop a pipeline of disease-modifying product candidates across a broad spectrum of genetic disease indications. As of 2026, the company has entered a collaboration with Eli Lilly to develop treatments for hearing loss using this platform technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Programmable Recombinase Gene Editing Platform A proprietary gene editing technology platform based on programmable recombinases that enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. The platform uses site-specific recombinases to correct gene mutations and is being developed for treating genetic diseases, including hearing loss via the Eli Lilly collaboration.

Quantifiable outcome

  • Potential $1.12 billion deal value from Eli Lilly partnership including upfront, R&D funding, and milestone payments
  • +1 more outcomes

Companies that use Seamless Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Seamless Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Seamless Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli LillycoreStrategic or Co-development Partner · 28 January 2026Eli Lilly entered into a global research collaboration and licensing agreement with Seamless Therapeutics to develop programmable recombinase-based gene-editing treatments for hearing loss. Seamless designs and programs site-specific recombinases to correct gene mutations, while Lilly gains exclusive license to advance candidates through preclinical and clinical development and commercialization. Deal could exceed $1.12 billion in total payouts for Seamless across upfront payments, R&D funding, and milestone terms.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Seamless Therapeutics competitors and assessment

Company assessment

Direct peers

  • Beam Therapeutics: Clinical-stage biotechnology company developing precision genetic medicines using base editing technology. Directly comparable to Seamless as a next-generation gene editing platform pursuing therapeutic applications, with differentiated editing chemistry targeting similar disease indications.
  • Editas Medicine: Clinical-stage gene editing company developing CRISPR-based medicines for serious diseases. Comparable to Seamless as a genome editing platform pursuing in vivo and ex vivo therapeutic applications, with overlapping target indications in genetic diseases.
  • Verve Therapeutics: Clinical-stage biotechnology company developing in vivo base editing treatments for cardiovascular disease. Comparable to Seamless as a gene editing platform pursuing in vivo therapeutic applications, with focus on durable treatments for genetic diseases.
  • Precision BioSciences: Clinical-stage biotechnology company developing ARCUS gene editing platform for in vivo and ex vivo therapeutic applications. Directly comparable to Seamless as a novel gene editing platform pursuing therapeutic applications with differentiated editing architecture.
  • Prime Medicine: Clinical-stage biotechnology company developing prime editing technology for precise gene corrections. Directly comparable to Seamless as a next-generation gene editing platform seeking to expand the scope of addressable genetic edits beyond traditional CRISPR/Cas approaches.
  • Intellia Therapeutics: Clinical-stage biotechnology company developing in vivo CRISPR/Cas9-based gene editing therapies. Directly comparable to Seamless as a genome editing platform company pursuing therapeutic applications across multiple genetic diseases, with overlapping modalities despite using a different editing architecture.
  • CRISPR Therapeutics: Clinical-stage biopharmaceutical company focused on CRISPR/Cas9 gene-editing therapies for hemoglobinopathies, oncology, and regenerative medicine. Directly comparable to Seamless as a genome editing platform company pursuing multiple therapeutic indications through a core editing technology.

Emerging players

  • Tessera Therapeutics: Preclinical-stage biotechnology company developing Gene Writing technology for precise genomic alterations. Comparable to Seamless as an emerging next-generation gene editing platform pursuing large DNA modifications for therapeutic applications.
  • Ensoma: Preclinical-stage biotechnology company developing in vivo gene editing and delivery technology for genomic medicines. Comparable to Seamless as an emerging gene editing platform, and notably a current board affiliation of Seamless CEO Albert Seymour, suggesting direct professional overlap in the field.

Broad incumbents

  • Sangamo Therapeutics: Clinical-stage biotechnology company developing zinc finger nuclease-based genome editing and gene therapy. Comparable to Seamless as a pioneering gene editing platform pursuing therapeutic applications across multiple genetic disease indications with a non-CRISPR editing approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Seamless Therapeutics social profiles

Digital presence

Seamless Therapeutics compliance and trust

Trust signal

Compliance1 record

Seamless Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seamless Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Seamless Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seamless Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seamless Therapeutics

What does Seamless Therapeutics do?

Seamless Therapeutics develops a proprietary programmable recombinase-based gene editing platform that enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. The platform is being applied to build a pipeline of disease-modifying gene therapy candidates, with the lead focus on hearing loss in collaboration with Eli Lilly, and is monetized through licensing and research collaboration agreements with pharmaceutical partners.

Is Seamless Therapeutics a public or private company?

Seamless Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Seamless Therapeutics founded?

Seamless Therapeutics was founded in 2023. It employs 11 to 50 people.

Where is Seamless Therapeutics based?

Seamless Therapeutics is headquartered in Dresden, Germany, in the Europe region.

How does Seamless Therapeutics make money?

Two revenue lines are on record. Research Collaboration Agreements are the primary driver. The others are licensing and Milestone Payments.

Who are Seamless Therapeutics's main competitors?

Direct peers on record are Beam Therapeutics, Editas Medicine, Verve Therapeutics, Precision BioSciences, Prime Medicine, Intellia Therapeutics and CRISPR Therapeutics. Emerging players are Tessera Therapeutics and Ensoma. Sangamo Therapeutics is listed as a broad incumbent.

Does Seamless Therapeutics have an API?

No public API is recorded for Seamless Therapeutics.

What industry is Seamless Therapeutics in?

Seamless Therapeutics's product category is Gene Editing Biotechnology Platform. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyEli Lilly bets on recombinases in $2.25bn Profluent R&D pact - Pharmaceutical TechnologyEli Lilly partnered with AI biotech Profluent to develop recombinases for large-scale gene editing, with Lilly paying an undisclosed upfront and funding R&D. The deal could earn Profluent up to $2.25bn in milestones and tiered royalties, and Lilly gained exclusive rights to selected recombinases.YahooEli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.Eli Lilly has partnered with Seamless Therapeutics, a German gene-editing start-up developing treatments for hearing loss, as part of its broader strategy to address the future patent cliff facing its GLP-1 drugs. Mounjaro and Zepbound currently account for 56% of Eli Lilly's sales, but these drugs' patents will eventually expire, creating revenue risk that the company is proactively working to mitigate. The partnership is one of several moves Eli Lilly is making to diversify its pipeline, including the acquisition of Ventyx Biosciences and multiple other acquisitions made in 2025.The Motley FoolEli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.Eli Lilly has partnered with German gene-editing start-up Seamless Therapeutics to develop treatments for hearing loss, while also acquiring Ventyx Biosciences to expand into oral inflammation treatments. These strategic moves aim to address the impending patent cliff facing the company's GLP-1 drugs Mounjaro and Zepbound, which currently account for 56% of Eli Lilly's sales. The partnerships are part of Eli Lilly's broader diversification strategy to replace future lost revenue as its blockbuster drugs face generic competition after patent expiration.SilverwoodpartnersHealthcare Private Placement and M&A Transactions Review Week Ending February 1, 2026This is a weekly compilation of healthcare venture funding and M&A transactions from Pitchbook Data covering the week ending February 1, 2026. The report includes 21 private placement transactions ranging from $5.9 million to $1.1 billion, with Seamless Therapeutics' $1.1 billion venture round from Eli Lilly being the largest financing, and 11 M&A transactions including Biogaran's $920 million acquisition by BC Partners and Bpifrance as the largest deal. Notable sectors represented include gene editing, synthetic biology, AI-driven drug discovery, and neurostimulation devices.The Motley FoolEli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless TherapeuticsEli Lilly has entered into a collaboration and licensing deal with Germany-based biotech Seamless Therapeutics worth over $1.12 billion to develop genetic medicines targeting hearing loss disorders. Seamless will design and program recombinases (DNA-editing proteins) while Lilly receives exclusive license rights to develop them into commercialized drugs, with payments including an upfront amount and undisclosed developmental and commercial milestones. Lilly is expanding its genetic medicine portfolio, having previously acquired Verve Therapeutics for $1.3 billion last July, and holds nearly $9.8 billion in cash as of late September 2025.BioPharma DiveLilly bets on Seamless, delving further into genetic medicine for hearing lossEli Lilly announced a partnership with Germany-based startup Seamless Therapeutics to develop gene editing treatments for hearing loss, gaining access to recombinase technology that can precisely modify specific areas of the genome. The deal could exceed $1.12 billion in total payouts for Seamless, including an upfront payment and various development milestones. The agreement expands Lilly's growing portfolio in genetic medicine, which includes existing programs for hearing loss inherited through its acquisition of Akuous and a prior partnership with Rznomics.StocktwitsEli Lilly Strikes $1.1 Billion Deal With Seamless Therapeutics To Develop Gene Therapies For Hearing LossEli Lilly announced a $1.1 billion deal with Seamless Therapeutics to develop gene therapies for hearing loss. This strategic partnership aims to advance treatments in the hearing loss therapy market.BioSpaceLilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With SeamlessEli Lilly is expanding its hearing loss treatment portfolio through a partnership with Seamless Therapeutics, valued at over $1.12 billion, which includes upfront payments and milestone-based payments. The partnership leverages Seamless's gene design platform to develop targeted therapies, building on Lilly's existing gene therapy AK-OTOF, which has shown promising results in restoring hearing. Additionally, Lilly is engaged in other hearing loss initiatives, including collaborations with Rznomics and competition from Regeneron.GenengnewsLilly, Seamless Ink Up-to-$1.12B Hearing Loss CollaborationEli Lilly has entered a global research collaboration and licensing agreement with German biotech startup Seamless Therapeutics to develop hearing loss treatments using Seamless's programmable recombinase gene-editing platform, with potential payments exceeding $1.12 billion for Seamless across upfront, R&D funding, and milestone terms. Seamless will design and program site-specific recombinases for correcting mutations in genes related to hearing loss, while Lilly gains exclusive license to advance candidates through preclinical and clinical development and commercialization. The deal, Seamless's first partnership with a biopharma giant, expands Lilly's hearing loss pipeline anchored by AK-OTOF, a gene therapy acquired from Akouos in 2022 for up to $610 million.GlobeNewswireSeamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing LossSeamless Therapeutics announced a global research collaboration and licensing agreement with Eli Lilly to develop recombinase-based treatments for hearing loss. Seamless will receive a guaranteed upfront payment and committed R&D funding, with total payments exceeding $1.12 billion, including potential milestones and excluding tiered royalties.